KOE:000250
Sam Chun Dang Pharm. Co., Ltd · KOE · Healthcare · KRW · FY for 2025
Figures on this page computed 2026-11-07 21:57 UTC
Last close
n/aKRW
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
751.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
3.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
2.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-15.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.25Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
What it pays out is the furthest below its sector's middle: 0.09 against 0.54 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.29x
Its own average over 10 years, 180.14B.
- Profit4.14x
Its own average over 10 years, 1.27B.
- Free cash flow4.28x
Its own average over 10 years, -8.49B.
- Debt1.81x
Its own average over 10 years, 38.49B.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 4.28 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 109.0 | 143.7 | 101.5 |
| 2018-12-31 | 108.5 | 100.5 | 101.5 |
| 2019-12-31 | 126.6 | 120.0 | 101.8 |
| 2020-12-31 | 113.2 | -11.1 | 102.7 |
| 2021-12-31 | 113.5 | -190.0 | 104.6 |
| 2022-12-31 | 120.3 | 67.0 | 104.6 |
| 2023-12-31 | 130.7 | -119.2 | 107.9 |
| 2024-12-31 | 143.1 | -125.3 | 109.1 |
| 2025-12-31 | 157.3 | 60.4 | 111.2 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Figures behind the shape
Growth
6.8%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate6.8%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
One-year change in net income148.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Returns on capital
3.2%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital3.2%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity1.9%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets0.9%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
45.6%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin45.6%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin3.6%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin2.3%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin-15.7%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
751.9xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings751.9x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
Price to book14.5x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA205.2x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio17.2x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.25safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.25
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio2.27
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage8.5x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score13.09
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
88.4%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Payout ratio88.4%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio-7.8x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- KRW
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.